PMID- 20374310
OWN - NLM
STAT- MEDLINE
DCOM- 20100624
LR  - 20151119
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 12
IP  - 1
DP  - 2009 Apr
TI  - Histological analysis of synovium by treatment of etanercept for rheumatoid 
      arthritis.
PG  - 7-13
LID - 10.1111/j.1756-185X.2009.01372.x [doi]
AB  - AIMS: In order to investigate the histological change in effect attenuation cases 
      of etanercept compared with methotrexate (MTX), we performed immunohistochemical 
      examination by seven different molecules. METHODS: We histologically assessed 
      synovial tissue from five MTX-treated rheumatoid arthritis (RA) patients as 
      control and six etanercept and MTX-treated RA patients after synovectomy by 
      arthroscopy. The synovium of both groups were assessed by hematoxylin and eosin 
      (HE) and we also analysed the expression of tumour necrosis factor-alpha 
      (TNF-alpha), interleukin-6 (IL-6), matrix metalloproteinase-3 (MMP-3), B-cell 
      precursors and mature B-cell transmembrane protein, CD20, macrophage marker, 
      CD68, bromodeoxyuridine (BrdU) and vascular endothelial growth factor (VEGF) by 
      immunohistochemistry. RESULTS: HE staining showed vascular and cell 
      proliferations of the synovium of the RA patients who received etanercept 
      compared with the control MTX group. TNF-alpha and IL-6 were expressed in both 
      groups.MMP-3 and CD68 expressed less significantly in the etanercept group 
      compared with the control (P < 0.05). CD20 strongly expressed in the etanercept 
      group significantly (P < 0.05). BrdU expressed in the synovium in the etanercept 
      group significantly (P < 0.05). VEGF was not found overall in both group. 
      CONCLUSION: Based on the histological change of synovium, treatment by etanercept 
      may be involved in vascular and cell proliferations with inhibition of the 
      expression of CD68 and MMP-3 in synovium of RA patients. These findings indicate 
      immunohistochemical change of synovium with etanercept is one of the mechanism of 
      efficacy of etanercept.
FAU - Suzuki, Yutaka
AU  - Suzuki Y
AD  - Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical 
      Center East, 2-1-10 Nishiogu, Arakawa, Tokyo 116-8567, Japan.
FAU - Inoue, Kazuhiko
AU  - Inoue K
FAU - Chiba, Junji
AU  - Chiba J
FAU - Inoue, Yasuo
AU  - Inoue Y
FAU - Kanbe, Katsuaki
AU  - Kanbe K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (CD68 antigen, human)
RN  - 0 (IL6 protein, human)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - OP401G7OJC (Etanercept)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aged
MH  - Antigens, CD/metabolism
MH  - Antigens, Differentiation, Myelomonocytic/metabolism
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/metabolism/pathology
MH  - Biomarkers/metabolism
MH  - Etanercept
MH  - Female
MH  - Fluorescent Antibody Technique, Indirect
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Matrix Metalloproteinase 3/metabolism
MH  - Methotrexate/*therapeutic use
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Synovial Membrane/*drug effects/metabolism/pathology
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2010/04/09 06:00
MHDA- 2010/06/25 06:00
CRDT- 2010/04/09 06:00
PHST- 2010/04/09 06:00 [entrez]
PHST- 2010/04/09 06:00 [pubmed]
PHST- 2010/06/25 06:00 [medline]
AID - APL1372 [pii]
AID - 10.1111/j.1756-185X.2009.01372.x [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2009 Apr;12(1):7-13. doi: 10.1111/j.1756-185X.2009.01372.x.